(Reuters) – Fennec Pharmaceuticals Inc said on Monday it expects the U.S. Food and Drug Administration to decline the marketing application for its drug to prevent hearing loss in children undergoing a type of chemotherapy.
(Reporting by Amruta Khandekar; Editing by Shounak Dasgupta)
